Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events
- Join the IC-ONC Community
- 2.0 CME Credits
- Create your own personalized posters
- Virtual reality animations
Thursday, June 25, 2020
6:00 PM – 8:00 PM EDT
06:00 PM Eastern; 05:00 PM Central; 04:00 PM Mountain; 03:00 PM Pacific
Arjun V. Balar, MD
Assistant Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY
Jeffrey S. Weber, MD, PhD
Deputy Director, Laura and Isaac Perlmutter Cancer Center
Co-Director, Melanoma Research Program
NYU Langone Health
Professor of Medicine, NYU Grossman School of Medicine
New York, NY
This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses, and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.
- Review the clinical utility of currently identified immune-related biomarkers and the benefits and limitations of different immune biomarker testing methodologies
- Incorporate immune-related biomarker testing to identify patients most likely to benefit from cancer immunotherapies administered alone or in combination
- Describe immune-related biomarker-driven pan-tumor studies, their designs, and the implications of their results for patient management
- Critically evaluate clinical data on current and emerging immune checkpoint inhibitors, with a focus on the unique type, incidence, and classification of immune-related adverse events (irAEs) across tumor types
- Describe how to diagnose irAEs associated with immunotherapies and current recommendations for their management
- Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship, including the role of multidisciplinary teams and emergent care considerations in the diagnosis and management of irAEs
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the care of patients with cancer who are treated or eligible for treatment with immunotherapy.
2.0 ANCC Contact Hour(s)
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hour(s) of continuing nursing education of RNs and APNs.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 2.0 knowledge-based contact hours for pharmacists/technicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at email@example.com
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.